Article

ASCRS 2020: Updates, improved injection technique from Eyepoint Pharmaceuticals

Author(s):

Alex Delaney-Gesing
Conferences|ASCRS

Ophthalmology Times' Sheryl Stevenson speaks with Eyepoint Pharmaceuticals' President/CEO Nancy Lurker and Chief Medical Officer Dario Paggiarino, MD, on the company's latest developments and research ahead of the ASCRS 2020 virtual meeting.

 

See more ASCRS meeting coverage here

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Related Content
ASCRS 2025: Companies share preview of data and presentations scheduled for 2025 annual meeting
April 25th 2025

ASCRS 2025: Companies share preview of data and presentations scheduled for 2025 annual meeting

Evaluating safety, efficacy of TP03 for Demodex blepharitis treatment
July 26th 2021

Evaluating safety, efficacy of TP03 for Demodex blepharitis treatment

ASCRS looks forward during milestone meeting
May 20th 2024

ASCRS looks forward during milestone meeting

EyePod
June 17th 2020

ASCRS 2020: Assessing aberration of monofocal toric IOL with enhanced optic recovery, alignment

Liver function test changes after fungal keratitis treatment
April 7th 2024

Liver function test changes after fungal keratitis treatment

A novel case of CNGA-3 achromatopsia: Structural changes seen over time
April 7th 2024

A novel case of CNGA-3 achromatopsia: Structural changes seen over time

© 2025 MJH Life Sciences

All rights reserved.